LG Chem 
Welcome,         Profile    Billing    Logout  
 40 Products   109 Diseases   40 Products   37 Trials   1902 News 


«12...345678910111213...1920»
  • ||||||||||  Gemiglo (gemigliptin) / Sanofi, LG Chem
    Preclinical, Journal:  Gemigliptin suppresses salivary dysfunction in streptozotocin-induced diabetic rats. (Pubmed Central) -  Jul 21, 2021   
    Therefore, gemigliptin has protective roles against salivary dysfunction observed in diabetes, mediated via antioxidant, anti-apoptotic, and salivary secretion mechanisms. These results may help in selecting a suitable drug for patients with diabetes experiencing salivary dysfunction.
  • ||||||||||  Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen, Nexavar (sorafenib) / Bayer, Amgen
    Clinical, Review, Journal:  Acquired Hypothyroidism in Patients with Metastatic Renal Cell Carcinoma Treated with Tyrosine Kinase Inhibitors. (Pubmed Central) -  Jul 17, 2021   
    The following keywords and descriptors were used during the search and were combined in a number of sequences in English and Chinese languages: protein kinase inhibitors (including sunitinib, pazopanib, tivozanib, cabozantinib, axitinib, sorafenib), hypothyroidism and renal cell carcinoma...The mechanism of hypothyroidism occurring is still unclear. Therefore, more studies are needed to clarify whether better outcomes are associated with TKI-induced hypothyroidism in mRCC patients, helping to maximize the treatment outcome of mRCC patients.
  • ||||||||||  Adalimumab BS MA (adalimumab biosimilar) / Mochida, LG Chem
    Journal:  Physicochemical and biological similarity assessment of LBAL, a biosimilar to adalimumab reference product (Humira®). (Pubmed Central) -  Jul 16, 2021   
    As indicated, this extensive analytical characterization and functional comparison assessment showed that LBAL was similar to Humira®, with minor differences of no clinical relevance. Taken together, our comparative assessment of physicochemical and biological attributes demonstrated that LBAL is structurally and functionally very similar to Humira®, supporting the biosimilarity of clinical efficacy and safety.
  • ||||||||||  Fotivda (tivozanib) / Kyowa Kirin, AVEO, Jazz, Nexavar (sorafenib) / Bayer, Amgen
    Journal:  Tivozanib, a highly potent and selective inhibitor of VEGF receptor tyrosine kinases, for the treatment of metastatic renal cell carcinoma. (Pubmed Central) -  Jul 16, 2021   
    Further, only picomolar concentrations of tivozanib are required to target these VEGF receptors and prevent phosphorylation; this potency prevents the debilitating side effects that occur with treatments whose mechanisms of action involve broad-spectrum tyrosine kinase inhibition. This review summarizes the growing body of evidence supporting tivozanib's efficacy and safety in the treatment of advanced renal cell carcinoma.
  • ||||||||||  Fotivda (tivozanib) / Kyowa Kirin, Jazz, LG Chem
    Trial completion date, Combination therapy, Metastases:  TiNivo study : Phase 1/2 Study of Tivozanib in Combination With Nivolumab in Subjects With RCC (clinicaltrials.gov) -  Jul 12, 2021   
    P1/2,  N=28, Active, not recruiting, 
    This review summarizes the growing body of evidence supporting tivozanib's efficacy and safety in the treatment of advanced renal cell carcinoma. Trial completion date: Dec 2020 --> Jul 2021
  • ||||||||||  Fotivda (tivozanib) / Kyowa Kirin, AVEO, Jazz, Nexavar (sorafenib) / Bayer, Amgen
    Clinical, Journal:  Final Data Analysis Supports Tivozanib as Superior Treatment for Patients With RCC. (Pubmed Central) -  Jul 3, 2021   
    Trial completion date: May 2021 --> Dec 2021 | Trial primary completion date: May 2021 --> Dec 2021 Tivozanib (Fotivda) significantly improved progression-free survival (PFS), compared with sorafenib (Nexavar), in patients with highly relapsed or refractory metastatic renal cell carcinoma (RCC), according to results from the phase 3 TIVO-3 trial presented at the 2020 American Society of Clinical Oncology Virtual Scientific Program.
  • ||||||||||  Fotivda (tivozanib) / Kyowa Kirin, AVEO, Jazz
    Review, Journal:  A new scenario in metastatic renal cell carcinoma: a SOG-GU consensus. (Pubmed Central) -  Jun 30, 2021   
    Among those approved TKIs, tivozanib has similar efficacy than others with a better safety profile. The use of prognostic factors is critical to the selection of optimal therapy.
  • ||||||||||  DTwP-HepB / LG Chem
    Clinical guideline, Journal:  Assessing vaccine introduction and uptake timelines in Gavi-supported countries: are introduction timelines accelerating across vaccine delivery platforms? (Pubmed Central) -  Jun 26, 2021   
    Factors accelerating timelines across delivery platforms included rapid product prequalifications by WHO, strong initial recommendations by the WHO Strategic Advisory Group of Experts (SAGE) on Immunization, achieving target product profiles on first vaccine licensure within a VPD and completing several VPD milestones at a global level prior to licensure. Milestones required for introduction in Gavi-supported countries should start prior or in parallel to licensure to accelerate uptake of vaccines delivered through diverse delivery platforms.
  • ||||||||||  Retrospective data, Journal:  Bullous pemphigoid and dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized controlled trials. (Pubmed Central) -  Jun 22, 2021   
    In conclusion, available data from randomized controlled trials seem to confirm the association between DPP-4 inhibitors and bullous pemphigoid. This association could be limited to one molecule of the class (i.e., linagliptin), although data on other DPP4-i (e.g., vildagliptin) are insufficient to rule out similar detrimental effects.
  • ||||||||||  Besivo (besifovir) / Gilead, LG Chem, Ildong
    Journal:  Another oral antiviral treatment, but still far away from HBV cure. (Pubmed Central) -  Jun 22, 2021   
    This association could be limited to one molecule of the class (i.e., linagliptin), although data on other DPP4-i (e.g., vildagliptin) are insufficient to rule out similar detrimental effects. No abstract available
  • ||||||||||  Nexavar (sorafenib) / Bayer, Amgen
    Journal:  Nitrogen Containing Heterocycles as Anticancer Agents: An Overview. (Pubmed Central) -  Jun 8, 2021   
    As per FDA databases nitrogen-based heterocycles in the drug design is almost 60% of unique smallmolecule drugs. Some of the nitrogen containing heterocyclic anti-cancer drugs are Axitinib, Bosutinib, Cediranib, Dasatanib (Sprycel®), Erlotinib (Tarceva®), Gefitinib (Iressa®), Imatinib (Gleevec®), Lapatinib (Tykerb®), Linifanib, Sorafenib (Nexavar®), Sunitinib (Sutent®), Tivozanib etc. In the present review, we shall focus on the overview of nitrogen containing heterocyclic active compounds as anti-cancer agents.
  • ||||||||||  DTwP-HepB / LG Chem
    Clinical, Journal:  Effect of Haemophilus influenzae Type b Vaccination on Nasopharyngeal Carriage Rate in Children, Tehran, 2019. (Pubmed Central) -  May 27, 2021   
    The Pentavac (pentavalent vaccine, manufactured by India, SII (DTwP-HepB-Hib)) was introduced to the Iranian National Immunization Plan in November 2014...Analysis in nonnursery's children aged 4 to 6 (unvaccinated) years showed that the lower educational level of father, mother, and family number correlated with increased odds of colonization of children with Hib. Our findings showed a significant decrease (60%) in the overall Hib nasopharyngeal carriage in healthy children under six years after 5 years after the start of Hib vaccination.
  • ||||||||||  Avastin (bevacizumab) / Roche, Opdivo (nivolumab) / Ono Pharma, BMS, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
    Journal:  Interdisciplinary recommendations for the treatment of advanced metastatic renal cell carcinoma (Pubmed Central) -  May 15, 2021   
    The use of both the combination of nivolumab + ipilimumab and cabozantinib is restricted to intermediate and high-risk patients...Temsirolimus is only approved for high-risk patients.Sunitinib and pazopanib can also be applied as second-line options - for pazopanib the use is restricted to the event of cytokine failure...Furthermore, the combination of lenvatinib + everolimus and axitinib are approved treatment options in the second-line and further settings...As in previous years, the experts intended to provide recommendations for clinical practice. The results are presented in this publication.
  • ||||||||||  Gemiglo (gemigliptin) / Sanofi, LG Chem
    Journal:  The vasodilatory effect of gemigliptin via activation of voltage-dependent K channels and SERCA pumps in aortic smooth muscle. (Pubmed Central) -  May 13, 2021   
    In addition, pre-treatment with sarcoplasmic/endoplasmic reticulum Ca-ATPase (SERCA) pump inhibitors thapsigargin and cyclopiazonic acid significantly reduced the vasodilatory effect of gemigliptin...These findings suggested that gemigliptin induces vasodilation through the activation of Kv channels and SERCA pumps independent of cAMP/PKA-related or cGMP/PKG-related signaling pathways and the endothelium. Therefore, caution is required when prescribing gemigliptin to the patients with hypotension and diabetes.
  • ||||||||||  TriptoSar (triptolide) / Pierre Fabre, Fotivda (tivozanib) / Kyowa Kirin, AVEO, Jazz
    Journal:  Prediction of potential therapeutic drugs against SARS-CoV-2 by using Connectivity Map based on transcriptome data. (Pubmed Central) -  May 1, 2021   
    SARS-CoV-2 can cause abnormal changes in a large number of molecules and related signaling pathways in human cells, among which IL-17 and TNF signaling pathways may play a key role in pathogenic process of SARS-CoV-2. Here, three compounds that may be effective for the treatment of SARS-CoV-2 were screened, which would provide new options for improving treatment of patients infected with SARS-CoV-2.
  • ||||||||||  Basalin (insulin glargine biosimilar) / Gan & Lee Pharma, LG Chem, Sandoz
    Trial completion:  GLITTER 2: Gan & Lee Insulin Glargine Target Type (2) Evaluating Research (clinicaltrials.gov) -  Apr 21, 2021   
    P3,  N=550, Completed, 
    Recruiting --> Active, not recruiting Active, not recruiting --> Completed